BenzingaSeptember 30, 2026 at 12:07 PM NY27 Days Ago
Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
